Welcome to LookChem.com Sign In|Join Free

CAS

  • or

16533-71-4

Post Buying Request

16533-71-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

16533-71-4 Usage

Chemical Properties

yellow crystalline powder

Uses

4-Methyl-3,5-dinitrobenzoic acid was used in characterization of the range of highly polar nitroaromatic compounds in water samples from a trinitrotoluene-contaminated waste disposal site. It was used as starting reagent for the asymmetric synthesis of the benzazocine core of FR900482.

Check Digit Verification of cas no

The CAS Registry Mumber 16533-71-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,5,3 and 3 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 16533-71:
(7*1)+(6*6)+(5*5)+(4*3)+(3*3)+(2*7)+(1*1)=104
104 % 10 = 4
So 16533-71-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H6N2O6/c1-4-6(9(13)14)2-5(8(11)12)3-7(4)10(15)16/h2-3H,1H3,(H,11,12)/p-1

16533-71-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-Methyl-3,5-dinitrobenzoic acid

1.2 Other means of identification

Product number -
Other names 3,5-Dinitro-4-methylbenzoic Acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:16533-71-4 SDS

16533-71-4Relevant articles and documents

Preparation method of 2,6-dihydroxytoluene

-

Paragraph 0022-0024; 0031-0033; 0040-0042; 0049-0060, (2018/04/27)

The invention discloses a preparation method of 2,6-dihydroxytoluene. The preparation method comprises the following steps of dissolving prepared 3,5-diamino-4-methylbenzoic acid in water, adding dilute sulphuric acid, stirring uniformly, adding ZnCl2, reducing the temperature to minus -2 to 2 DEG C after stirring uniformly, dropwise adding a sodium nitrite solution into the mixture, continuouslystirring to react for 5-6 hours after the dropwise adding is finished, then adding water and dilute sulphuric acid, mixing uniformly, then heating for boiling, reacting for 30-45 minutes, then addingsodium hydroxide, carrying out reflux reaction for 1-2 hours, cooling to room temperature, adding diethyl ether, stirring for 20-40 minutes, then adding zeolite, stirring and mixing for 1-2 hours, carrying out reduced-pressure distillation after filtering, and preparing the 2,6-dihydroxytoluene. The preparation method disclosed by the invention has the beneficial effects that the raw-material costis low, the operation is simple, safe and reliable, the requirements for the environmental conditions are mild, the product purity is high and the yield is high.

An atom economical method for the direct synthesis of quinoline derivatives from substituted o-nitrotoluenes

Liu, Guiyan,Yi, Maocong,Liu, Lu,Wang, Jingjing,Wang, Jianhui

, p. 2911 - 2914 (2015/02/19)

A highly efficient one-pot procedure for the preparation of substituted quinolines from substituted o-nitrotoluenes with electron-withdrawing groups and olefins (acrylic esters and acrylonitriles) using a cesium catalyst has been developed. A plausible [2+4] cycloaddition mechanism is proposed. This method uses nitroaromatic compounds as the starting materials to give quinoline derivatives in good to high yields under mild conditions with no transition metal catalysis. It provides an atom economical pathway for the synthesis of quinoline derivatives which could be used in industrial processes.

FLUORO-SUBSTITUTED COMPOUNDS AS KINASE INHIBITORS AND METHODS OF USE THEREOF

-

Page/Page column 25, (2011/02/24)

The present invention provides for novel compounds of Formula I and pharmaceutically acceptable salts and solvates thereof which have kinase inhibitor activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating and preventing a Bcr-Abl, c-Kit or PDGF-R mediated disorder for which one or more kinase inhibitor is indicated, including neoplasia such as chronic myelogenous leukemia or gastrointestinal stromal tumors. The present invention also provides for processes of making the compounds of Formula I, including salts and solvates thereof, and pharmaceutical compositions comprising the same.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 16533-71-4